| NRG-GY007 | A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
| Closed to Accrual | I/II | >Gynecologic [GY] | Ovarian |
| NRG-GY033 | A Phase II Study of Androgen Receptor (AR) Inhibition by Darolutamide in combination with Leuprolide Acetate and Exemestane in Recurrent Adult-Type Ovarian Granulosa Cell Tumors
| Temporarily Closed to Accrual | II | >Gynecologic [GY] | Ovarian |
| EAY191-N4 | Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers - A ComboMATCH Treatment Trial
| Open to Accrual | II | >Gynecologic [GY] | Multiple |
| NRG-GY029 | A Randomized Phase II trial comparing the combination of PI3K inhibitor Copanlisib (BAY 80-6946) and PARP inhibitor Olaparib (AZD2281) to standard chemotherapy in patients with recurrent platinum resistant ovarian, fallopian tube, or primary peritoneal cancer who have progressed through prior PARP inhibitor therapy
| Closed to Accrual | II | >Gynecologic [GY] | Ovarian |
| NRG-GY027 | NRG-GY027: PHASE I/IB SAFETY AND PHARMACODYNAMIC STUDY OF NEOADJUVANT (NACT) PACLITAXEL AND CARBOPLATIN WITH IPATASERTIB AS INITIAL THERAPY OF OVARIAN CANCER PTMA 100805
| Open to Accrual | I | >Gynecologic [GY] | Ovarian |
| NRG-GY023 | A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab | Closed to Accrual | II | >Gynecologic [GY] | Ovarian |
| GOG-0268 | A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: 683864, IND #61010) in Combination with Carboplatin and Paclitaxel followed by Temsirolimus Consolidation as First-line Therapy in the Treatment of Clear Cell Carcinoma of the Ovary. | Closed to Accrual | II | >Gynecologic [GY] | Ovarian |
| GOG-0214 | Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer (IND# 79,610)
| Terminated | II | >Gynecologic [GY] | Ovarian |
| GOG-0199 | Prospective Study of Risk-Reducing Salpingo-Oophorectomy and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer
| Terminated | I | >Gynecologic [GY] | Ovarian |
| NRG-GY021 | A Phase II Randomized Trial of Olaparib versus Olaparib plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer | Closed to Accrual | II | >Gynecologic [GY] | Ovarian |
| NRG-GY019 | A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum | Open to Accrual | III | >Gynecologic [GY] | Ovarian |
| NRG-GY014 | A Phase II Study of Tazemetostat (EPZ-6438) (IND # 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma | Closed to Accrual | II | >Gynecologic [GY] | Ovarian |
| GOG-9923 | A Phase I Study of Carboplatin/Paclitaxel/CTEP-Supplied Bevacizumab(NSC #704865, IND #7921)and CTEP-Supplied Agent ABT-888(NSC #737664,IND# 77840)in Newly Diagnosed Patients with Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary PeritCancer | Terminated | I | >Gynecologic [GY] | Ovarian |
| GOG-0260 | A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (IND 110072) (NCT# 00888615). | Terminated | II | >Gynecologic [GY] | Ovarian |
| GOG-0186K | A Randomized Phase II Study of NCI Supplied Cabozantinib (NSC #761968 IND #116059) versus weekly paclitaxel (NSC #673089) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Terminated | II | >Gynecologic [GY] | Ovarian |
| NRG-GY016 | A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary | Terminated | II | >Gynecologic [GY] | Ovarian |
| NRG-GY001 | A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women with Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum | Terminated | II | >Gynecologic [GY] | Ovarian |
| GOG-0213 | A Phase III Randomized Controlled Clinical Trial Of Carboplatin and Paclitaxel or Gemcitabine) Alone or in Combination with Bevacizumab (NSC #704865, IND #113912) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrenovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865, IND #113912) | Closed to Accrual | III | >Gynecologic [GY] | Ovarian |
| NRG-GY005 | A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS). | Closed to Accrual | II/III | >Gynecologic [GY] | Ovarian |
| NRG-GY004 | A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Closed to Accrual | III | >Gynecologic [GY] | Ovarian |
| GOG-0239 | A Phase II Trial of AZD6244 (NSC #748727, IND #77782) in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum | Terminated | II | >Gynecologic [GY] | Ovarian |
| NRG-GY003 | A Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer | Closed to Accrual | II | >Gynecologic [GY] | Ovarian |
| GOG-0225 | Can Diet and Physical Activity Modulate Ovarian or Primary Peritoneal Cancer Progression-Free Survival? | Closed to Accrual | III | >Gynecologic [GY] | Ovarian |
| NRG-GY009 | A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab (IND #134427) Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer | Closed to Accrual | II/III | >Gynecologic [GY] | Ovarian |
| GOG-0186H | A Randomized Phase II Evaluation of Weekly Paclitaxel (NSC# 673089) versus Weekly Paclitaxel with Oncolytic Reovirus (Reolysin NSC # 729968, BB-IND #13370) in the Treatment of Recurrent or Persistent Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Terminated | II | >Gynecologic [GY] | Ovarian |
| GOG-0281 | A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer | Closed to Accrual | II/III | >Gynecologic [GY] | Ovarian |
| GOG-9928 | A Phase I study of the safety of intraperitoneal EGEN-001 (IL-12 plasmid formulated with PEG-PEI-Cholesterol lipopolymer) administered in combination with pegylated liposomal doxorubicin (PLD) in recurrent ovarian cancer patients. The purpose of this studtermine the safety of EGEN-001 IP plus PLD treatment in platinum-recurrent ovarian cancer patients. | Terminated | I | >Gynecologic [GY] | Ovarian |
| GOG-9924 | A Phase I Pharmacokinetic Study of Intraperitoneal CTEP-Supplied Agent Bortezomib (PS-341, NSC 681239, IND# 58443) and Carboplatin (NSC# 241240)in Patients with Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Terminated | I | >Gynecologic [GY] | Ovarian |
| GOG-0280 | A Phase II Eval of the Poly(ADP-Ribose)Polymerase (PARP)-1 and -2 Inhibitor Veliparib (ABT-888)(NSC #737644) in the tx of Persistent or Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Ca in Patients who carry a germline BRCA 1 or 2 Mutation | Terminated | II | >Gynecologic [GY] | Ovarian |
| RTOG-0724 | Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy | Closed to Accrual | III | >Gynecologic [GY] | Ovarian |